UNPRECEDENTED PRECLINICAL EFFICACY OF JNJ-1802, A NOVEL PAN-SEROTYPE DENGUE ANTIVIRAL SMALL MOLECULE, AGAINST DENGUE VIRUS IN NON-HUMAN PRIMATE AND MURINE MODELS

被引：0

作者：

Goethals, Olivia ^{[1
]}

Kaptein, Suzanne J. F. ^{[2
]}

Kesteleyn, Bart ^{[3
]}

Bonfanti, Jean-Francois ^{[4
]}

Jonckers, Tim H. M. ^{[3
]}

Marchand, Arnaud ^{[5
]}

Verschoor, Ernst ^{[6
]}

Verstrepen, Babs ^{[6
]}

Van Wesenbeeck, Liesbeth ^{[3
]}

Ackaert, Oliver ^{[7
]}

Straetemans, Roel ^{[3
]}

Lachau-Durand, Sophie ^{[3
]}

Geluykens, Peggy ^{[3
]}

Crabbe, Marjolein ^{[3
]}

Thys, Kim ^{[3
]}

Bardiot, Dorothee ^{[5
]}

Stoops, Bart ^{[3
]}

Dallmeier, Kai ^{[2
]}

Putnak, Robert J. ^{[8
]}

McCracken, Michael K. ^{[8
]}

Gromowski, Gregory D. ^{[8
]}

Rutvisuttinunt, Wiriya ^{[8
]}

Jarman, Richard G. ^{[8
]}

Karasavvas, Nicos ^{[8
]}

Touret, Franck ^{[9
]}

Querat, Gilles ^{[9
]}

de lamballerie, Xavier ^{[9
]}

Kiemel, Dominik ^{[10
]}

Chatel-Chaix, Laurent ^{[10
]}

Munster, Max ^{[10
]}

Milligan, Gregg ^{[11
]}

Beasley, David ^{[11
]}

Bourne, Nigel ^{[11
]}

Barrett, Alan D. T. ^{[11
]}

Raboisson, Pierre ^{[3
]}

Simmen, Kenny ^{[3
]}

Chaltin, Patrick ^{[5
,12
]}

Bartenschlager, Ralf ^{[10
,13
]}

Bogers, Willy ^{[6
]}

Neyts, Johan ^{[2
,14
]}

Van Loock, Marnix ^{[1
]}

机构：

[1] Janssen Pharmaceut NV, Janssen Global Publ Hlth, Beerse, Belgium

[2] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Rega Inst Med Res, Lab Virol & Chemotherapy, Leuven, Belgium

[3] Janssen Pharmaceut NV, Janssen Res & Dev, Beerse, Belgium

[4] Janssen Cilag, Janssen Infect Dis Discovery, Val De Reuil, France

[5] Cistim Leuven Vzw, Bioincubator 2, Leuven, Belgium

[6] Biomed Primate Res Ctr, Dept Virol, Rijswijk, Netherlands

[7] Janssen Pharmaceut NV, Janssen Quantitat Sci, Beerse, Belgium

[8] Walter Reed Army Inst Res, Viral Dis Branch, Silver Spring, MD USA

[9] Aix Marseille Univ, Unite Virus Emergents, IRD 190, Inserm 1207,IHU Mediterranee Infect, Marseille, France

[10] Heidelberg Univ, Dept Infect Dis, Mol Virol, Heidelberg, Germany

[11] Univ Texas Med Branch Hlth, Sealy Inst Vaccine Sci, Galveston, TX USA

[12] Katholieke Univ Leuven, Ctr Drug Design & Discovery CD3, Bioincubator 2, Leuven, Belgium

[13] German Ctr Infect Res, Heidelberg Partner Site, Heidelberg, Germany

[14] Global Virus Network, Leuven, Belgium

来源：

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE | 2021年 / 105卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

1291

引用

页码：413 / 414

页数：2

共 6 条

[1] Discovery of JNJ-1802, a First-in-Class Pan-Serotype Dengue Virus NS4B Inhibitor
Kesteleyn, Bart
Bonfanti, Jean-Francois
Bardiot, Dorothee
De Boeck, Benoit
Goethals, Olivia
Kaptein, Suzanne J. F.
Stoops, Bart
Coesemans, Erwin
Fortin, Jerome
Muller, Philippe
Doublet, Frederic
Carlens, Gunter
Koukni, Mohamed
Smets, Wim
Raboisson, Pierre
Chaltin, Patrick
Simmen, Kenny
Van Loock, Marnix
Neyts, Johan
Marchand, Arnaud
Jonckers, Tim H. M.
JOURNAL OF MEDICINAL CHEMISTRY, 2024, 67 (05) : 4063 - 4082
[2] Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers
Ackaert, Oliver
Vanhoutte, Frederic
Verpoorten, Nathalie
Buelens, Annemie
Lachau-Durand, Sophie
Lammens, Lieve
Hoetelmans, Richard
Van Loock, Marnix
Herrera-Taracena, Guillermo
CLINICAL INFECTIOUS DISEASES, 2023, 77 (06) : 857 - 865
[3] Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers (vol 77, pg 857, 2023)
Ackaert
CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 283 - 283
[4] SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A NOVEL PAN-SEROTYPE DENGUE ANTIVIRAL SMALL MOLECULE IN A PHASE 1, DOUBLE-BLIND, RANDOMIZED, DOSE-ESCALATION STUDY
Ackaert, Oliver
Vanhoutte, Fredric
Verpoorten, Nathalie
Buelens, Annemie
Lachau-Durand, Sophie
Lammens, Lieve
Van Loock, Marnix
Herrera-Taracena, Guillermo
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2021, 105 (05): : 186 - 186
[5] First-in-human trial evaluating safety and pharmacokinetics of AT-752, a novel nucleotide prodrug with pan-serotype activity against dengue virus
Zhou, Xiao-Jian
Lickliter, Jason
Montrond, Maureen
Ishak, Laura
Pietropaolo, Keith
James, Dayle
Belanger, Bruce
Horga, Arantxa
Hammond, Janet
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (05)
[6] NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models
Moquin, Stephanie A.
Simon, Oliver
Karuna, Ratna
Lakshminarayana, Suresh B.
Yokokawa, Fumiaki
Wang, Feng
Saravanan, Chandra
Zhang, Jin
Day, Craig W.
Chan, Katherine
Wang, Qing-Yin
Lu, Siyan
Dong, Hongping
Wan, Kah Fei
Lim, Siew Pheng
Liu, Wei
Seh, Cheah Chen
Chen, Yen-Liang
Xu, Haoying
Barkan, David T.
Kounde, Cyrille S.
Sim, Wei Lin Sandra
Wang, Gang
Yeo, Hui-Quan
Zou, Bin
Chan, Wai Ling
Ding, Mei
Song, Jae-Geun
Li, Min
Osborne, Colin
Blasco, Francesca
Sarko, Christopher
Beer, David
Bonamy, Ghislain M. C.
Sasseville, Vito G.
Shi, Pei-Yong
Diagana, Thierry T.
Yeung, Bryan K. S.
Gu, Feng
SCIENCE TRANSLATIONAL MEDICINE, 2021, 13 (579)

← 1 →